# US 2009/0156976 A1 · Devices and Methods for Extracorporeal Ablation of Circulating Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0156976 A1
- Document ID: US20090156976A1
- Status: Published application
- Kind: A1
- Application number: 12/227,843
- Filed: 2008-02-29
- Published: 2009-06-18
- Earliest claimed: 2007-03-01
- Assignees: Nanospectra Biosciences, Inc.
- Inventors: Martin Korbling; J. Donald Payne; Christopher L. Coleman; Jon A. Schwartz
- Web page: https://patentgrep.com/patent/US20090156976A1

## CPC

- A61M 1/3681: {by irradiation}
- A61M 1/3618: {Magnetic separation}
- A61M 1/3683: {using photoactive agents}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61M 1/369: {Temperature treatment}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.

## Claims

### Claim 1

A method for the extracorporeal ablation of target cells circulating in blood of an organism, said method comprising:
introducing an exogenous material into the blood wherein the exogenous material is adapted to preferentially associate with the target cells;
allowing such exogenous material to preferentially associate with the target cells;
providing an extracorporeal continuous flow pathway for accessing the blood and subsequently returning the blood to the body continuously;
allowing the blood to flow through the extracorporeal continuous flow pathway;
applying an external energy from an external energy source to the blood in a portion of the extracorporeal continuous flow pathway at an ex vivo ablation device;
allowing the application of the external energy to activate the exogenous material so as to result in the damage or death of the target cells; and
allowing the blood to return continuously to the body from the extracorporeal continuous flow pathway.

### Claim 2 (depends on 1)

The method of claim 1 wherein the external energy comprises electromagnetic radiation.

### Claim 3 (depends on 2)

The method of claim 2 wherein the electromagnetic radiation is ultraviolet radiation, visible light, infrared light, microwave radiation, radiowaves, or any combination thereof.

### Claim 4 (depends on 1)

The method of claim 1 wherein the exogenous material is adapted to preferentially absorb electromagnetic radiation.

### Claim 5 (depends on 1)

The method of claim 1 wherein the exogenous material is adapted to convert a portion of the electromagnetic radiation to heat upon exposure to electromagnetic radiation.

### Claim 6 (depends on 4)

The method of claim 4 wherein the exogenous material is selected from the group consisting of metal colloids, carbon particles, nanoshells, nanorods, buckyballs, carbon fullerenes, nanocubes, nanostars, and indocyanine green encapsulated in nanoparticles.

### Claim 7 (depends on 1)

The method of claim 1 wherein the exogenous material comprises photo synthesizers.

### Claim 8 (depends on 1)

The method of claim 1 wherein the exogenous material is selected from the group consisting of iron oxides and paramagnetic particles that emit heat when exposed to alternating magnetic fields.

### Claim 9 (depends on 1)

The method of claim 1 wherein the exogenous material comprises a light-activated prodrug.

### Claim 10 (depends on 1)

The method of claim 1 wherein the external energy comprises acoustic energy.

### Claim 11 (depends on 10)

The method of claim 10 wherein the exogenous material is selected from among materials that generate heat when exposed to acoustic energy.

### Claim 12 (depends on 1)

The method of claim 1 wherein the preferential association of the exogenous material with the target cells is by way of a ligand attached to the exogenous material.

### Claim 13 (depends on 12)

The method of claim 12 wherein said ligand is an antibody, an antibody fragment, an aptamer, a peptide, a chemical entity that has an affinity for a surface molecule on the target cells, or any combination thereof.

### Claim 14 (depends on 12)

The method of claim 12 wherein said ligand results in the attachment of the exogenous material to the surface of the target cells.

### Claim 15 (depends on 12)

The method of claim 12 wherein said ligand results in the endocytosis of the exogenous material by the target cells.

### Claim 16 (depends on 1)

The method of claim 1 wherein the chemical structure of the exogenous material results in the endocytosis of the exogenous material by the target cells.

### Claim 17 (depends on 1)

The method of claim 1 wherein the target cells are cancer cells, a type of T-cell or B-cell, a virus, a fungus, a parasite, bacterial cells, or any combination thereof.

### Claim 18 (depends on 2)

The method of claim 2 wherein the external energy is a combination of electromagnetic energy and acoustic energy.

### Claim 19 (depends on 1)

The method of claim 1 wherein introducing the exogenous material into the blood occurs before allowing the blood to flow through the extracorporeal continuous flow pathway.

### Claim 20 (depends on 1)

The method of claim 1 wherein the exogenous material is introduced into the blood during the passage through the extracorporeal continuous flow pathway.

### Claim 21 (depends on 1)

The method of claim 1 further comprising elevating the temperature of the blood prior to or during passage through the ex vivo ablation device so as to assist in ablation of the target cells.

### Claim 22 (depends on 1)

The method of claim 1 wherein the ex vivo ablation device is made with a reflecting surface to allow energy transmitted on one side of the ex vivo ablation device to be reflected back into the ex vivo ablation device.

### Claim 23 (depends on 1)

The method of claim 1 wherein the ex vivo ablation device is exposed to external energy from more than one side of the ex vivo ablation device to provide additional exposure of energy through the blood.

### Claim 24 (depends on 1)

The method of claim 1 further comprising providing a cooler and removing energy from the blood by way of the cooler.

### Claim 25 (depends on 1)

The method of claim 1 further comprising removing energy from the blood by a cooled or absorptive material.

### Claim 26 (depends on 2)

The method of claim 2 further comprising providing a magnetic device and exposing a portion of the extracorporeal continuous flow pathway to a magnetic field so as to segregate the target cells from the blood.

### Claim 27 (depends on 26)

The method of claim 26 wherein applying the external energy comprises applying external energy to the segregated target cells.

### Claim 28 (depends on 1)

The method of claim 1 wherein a portion of the ex vivo ablation device is adapted to preferentially associate with target cells by way of an antibody or fragment thereof, an aptamer, a peptide, or chemical entity that has an affinity for a cell surface molecule on the target cells so as to capture the target cells circulating in blood; allowing the ex vivo ablation device to capture the target cells; and wherein applying the external energy comprises applying external energy to the captured target cells.

### Claim 29 (depends on 1)

The method of claim 1 further comprising applying an external electric field to the ex vivo ablation device to segregate the target cells from the blood.

### Claim 30 (depends on 1)

The method of claim 1 wherein the external energy comprises ionizing radiation.

### Claim 31 (depends on 1)

The method of claim 1 wherein the external energy from the energy source comprises more than one form of energy.

### Claim 32

A device for the extracorporeal ablation of target cells circulating in blood comprising:
an extracorporeal continuous flow pathway for accessing the blood and subsequently continuously returning of the blood to the body after treatment; and
an energy generator for applying an external energy to the blood in a portion of the extracorporeal continuous flow pathway such that target cells in the blood are preferentially damaged or destroyed.

### Claim 33 (depends on 32)

The device of claim 32 further comprising exogenous material for introduction into blood wherein the exogenous material is adapted to preferentially associate with the target cells in the blood.

### Claim 34 (depends on 32)

The device of claim 32 wherein the energy generator is adapted to produce acoustic energy.

### Claim 35 (depends on 34)

The device of claim 34 wherein the exogenous material comprises a material that generates heat when exposed to acoustic energy.

### Claim 36 (depends on 33)

The device of claim 33 wherein the preferential association of the exogenous material with the target cells is by way of a ligand attached to the exogenous material.

### Claim 37 (depends on 36)

The device of claim 36 wherein said ligand is an antibody, an antibody fragment, an aptamer, a peptide, a chemical entity that has an affinity for a surface molecule on the target cells, or a combination thereof.

### Claim 38 (depends on 36)

The device of claim 36 wherein said ligand results in the attachment of the exogenous material to the surface of the target cells.

### Claim 39 (depends on 36)

The device of claim 36 wherein said ligand results in the endocytosis of the exogenous material by the target cells.

### Claim 40 (depends on 33)

The device of claim 33 wherein the chemical structure of the exogenous material results in the endocytosis of the exogenous material by the target cells.

### Claim 41 (depends on 33)

The device of claim 33 wherein the target cells are cancer cells, a type of T-cells or B-cells, a virus, a fungus, a parasite or bacterial cells.

### Claim 42 (depends on 33)

The device of claim 33 wherein the external energy generator is adapted to produce a combination of electromagnetic energy and acoustic energy.

### Claim 43 (depends on 33)

The device of claim 33 wherein the ex vivo ablation device is made with a reflecting surface to allow energy transmitted on one side of the ex vivo ablation device to be reflected back into the ex vivo ablation device.

### Claim 44 (depends on 33)

The device of claim 33 wherein the ex vivo ablation device is adapted to receive external energy from more than one side of the ex vivo ablation device to provide additional exposure of energy through the blood.

### Claim 45 (depends on 33)

The device of claim 33 further comprising a cooler in the extracorporeal continuous flow pathway for cooling the blood.

### Claim 46 (depends on 33)

The device of claim 33 further comprising a magnetic device adapted to expose a portion of the extracorporeal continuous flow pathway to a magnetic field.

### Claim 47 (depends on 33)

The device of claim 33 wherein a portion of the ex vivo ablation device comprises an antibody or fragment thereof, an aptamer, a peptide, or other chemical entity that has an affinity for a cell surface molecule on the target cells for capturing the target cells circulating in blood.

### Claim 48 (depends on 33)

The device of claim 33 wherein the ex vivo ablation device is adapted to expose an external electric field to the blood to segregate the target cells from the blood.

### Claim 49 (depends on 33)

The device of claim 33 wherein the ex vivo ablation device is adapted to expose the blood to ionizing radiation.

### Claim 50

A system for the extracorporeal ablation of targets within blood, said system comprising:
an extracorporeal continuous flow pathway for access of blood and subsequent continuous return to a biological body;
an extracorporeal blood pump for providing a motive force to continuously flow the blood from the biological body and returning the blood to the biological body in a closed loop;
an energy source adjacent to said extracorporeal continuous flow pathway; and
a plurality of nanoparticles that preferentially associate with target cells within the blood, wherein said nanoparticles are adapted to receive energy from said energy source and release the energy to said target cells.

### Claim 51 (depends on 50)

The system of claim 50 wherein said extracorporeal blood pump comprises a blood circuit having an inlet line leading to the extracorporeal blood pump and an outlet line from the extracorporeal blood pump; at least one infusion line comprising at least a pre-infusion branch connected to the inlet line of the blood circuit; and at least one auxiliary fluid container for supplying said at least one infusion line.

### Claim 52

A system for the extracorporeal ablation of targets within blood, said system comprising:
a continuous-flow, extracorporeal circulation device including an extracorporeal blood flow pathway;
an external energy source adjacent a portion of said extracorporeal blood flow pathway;
blood containing target cells disposed in said extracorporeal blood flow pathway; and
energy absorbing/converting particles attached to said targets.

### Claim 53 (depends on 52)

The system of claim 52 wherein the external energy source comprises electromagnetic energy.

### Claim 54 (depends on 53)

The system of claim 53 wherein the electromagnetic energy is selected from a group consisting of ultraviolet, visible, or infrared light, microwaves, and radiowaves.

### Claim 55 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are capable of absorbing electromagnetic energy.

### Claim 56 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are capable of emitting heat upon exposure to electromagnetic energy.

### Claim 57 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are nanoparticles.

### Claim 58 (depends on 57)

The system of claim 57 wherein said nanoparticles are selected from the group consisting of metal colloids, carbon particles, nanoshells, nanorods, buckyballs, carbon fullerenes, nanocubes, nanostars, and indocyanine green encapsulated in nanoparticles.

### Claim 59 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are activated upon exposure to electromagnetic radiation.

### Claim 60 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are photsynthesizers.

### Claim 61 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are paramagnetic particles that emit heat when exposed to alternating magnetic fields.

### Claim 62 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are iron oxides.

### Claim 63 (depends on 52)

The system of claim 52 wherein said energy absorbing/converting particles are light-activated prodrugs.

### Claim 64

A method for the extracorporeal ablation of target cells circulating in the blood of a biological body, said method comprising:
attaching, in vivo, energy absorbing/converting particles to circulating blood containing target cells to form conjugates of particles and target cells;
extracorporeally circulating the blood outside the biological body;
during extracorporeal circulation, exposing the conjugates to external energy while outside the biological body so as to treat the blood; and
circulating said treated blood back into the biological body in a continuous flow system.

### Claim 65

A method for the ablation of target cells circulating in the blood of a biological body, said method comprising:
extracorporeally circulating blood containing target cells outside a biological body;
attaching energy absorbing/converting particles to said target cells in said extracorporeally circulating blood to form conjugates of particles and target cells;
during extracorporeal circulation, exposing the conjugates to external energy while outside the biological body so as to treat the blood; and
circulating said treated blood back into the biological body in a continuous flow system.
